--- title: "Invivyd (NASDAQ:IVVD) Insider Sells $26,824.32 in Stock" type: "News" locale: "en" url: "https://longbridge.com/en/news/296284945.md" description: "Invivyd insider Jill Andersen sold shares totaling approximately $52,617 to cover tax withholding obligations on equity awards. The transactions involved selling 37,256 shares at $0.72 and 30,706 shares at $0.84, reducing her position by over 10%. Additionally, Invivyd reported Q2 earnings missing estimates, with a 'Hold' consensus rating from analysts despite mixed institutional buying activity." datetime: "2026-08-19T01:08:26.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296284945.md) - [en](https://longbridge.com/en/news/296284945.md) - [zh-HK](https://longbridge.com/zh-HK/news/296284945.md) generator: "portal-rs" --- # Invivyd (NASDAQ:IVVD) Insider Sells $26,824.32 in Stock Invivyd, Inc. (NASDAQ:IVVD - Get Free Report) insider Jill Andersen sold 37,256 shares of Invivyd stock in a transaction on Monday, August 17th. The stock was sold at an average price of $0.72, for a total value of $26,824.32. Following the completion of the transaction, the insider owned 314,480 shares in the company, valued at $226,425.60. The trade was a 10.59% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Jill Andersen also recently made the following trade(s): - On Tuesday, August 18th, Jill Andersen sold 30,706 shares of Invivyd stock. The shares were sold at an average price of $0.84, for a total value of $25,793.04. ## Invivyd Trading Up 17.2% Shares of NASDAQ:IVVD traded up $0.13 during midday trading on Tuesday, reaching $0.87. The company had a trading volume of 7,732,095 shares, compared to its average volume of 3,061,089. Invivyd, Inc. has a 1-year low of $0.48 and a 1-year high of $3.07. The company has a fifty day simple moving average of $0.77 and a two-hundred day simple moving average of $1.23. Invivyd (NASDAQ:IVVD - Get Free Report) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.03). The business had revenue of $14.29 million during the quarter, compared to analysts' expectations of $14.40 million. Invivyd had a negative return on equity of 59.73% and a negative net margin of 183.90%. Sell-side analysts forecast that Invivyd, Inc. will post -0.52 earnings per share for the current year. ## Wall Street Analyst Weigh In A number of research firms recently issued reports on IVVD. Weiss Ratings reissued a "sell (d-)" rating on shares of Invivyd in a research report on Friday, July 24th. Wall Street Zen lowered Invivyd from a "hold" rating to a "strong sell" rating in a research report on Saturday, May 16th. HC Wainwright reaffirmed a "buy" rating on shares of Invivyd in a research note on Tuesday. Finally, BTIG Research reiterated a "buy" rating on shares of Invivyd in a report on Tuesday, July 7th. Three analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $8.00. **Get Our Latest Analysis on IVVD** ## Institutional Investors Weigh In On Invivyd Hedge funds have recently modified their holdings of the business. United Capital Financial Advisors LLC acquired a new position in Invivyd in the 2nd quarter valued at approximately $84,000. Bank of America Corp DE acquired a new position in shares of Invivyd in the second quarter valued at $311,000. Jupiter Topco LLC bought a new position in Invivyd in the second quarter worth $30,048,000. ADAR1 Capital Management LLC acquired a new stake in Invivyd during the second quarter worth $3,322,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in Invivyd during the second quarter worth $52,000. 70.36% of the stock is owned by institutional investors. ## Invivyd Company Profile (Get Free Report) Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. ## Featured Articles - Five stocks we like better than Invivyd - The AI Boom Is Turning This Cable Maker Into a Stock to Watch - A Star Investor Just Trimmed Amazon—Here's What It means - Wendy’s Deal Buzz May Give Fast-Food Investors a New Reason to Look - Home Depot Analysts See a Path to $375 and Beyond *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.* Continue following MarketBeat Add MarketBeat as your preferred source on Google to see our latest stories in your feed. Add As Preferred Source ## Should You Invest $1,000 in Invivyd Right Now? Before you consider Invivyd, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Invivyd wasn't on the list. While Invivyd currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [IVVD.US](https://longbridge.com/en/quote/IVVD.US.md) - [BAC.US](https://longbridge.com/en/quote/BAC.US.md) - [MFC.US](https://longbridge.com/en/quote/MFC.US.md) - [AMZN.US](https://longbridge.com/en/quote/AMZN.US.md) - [WEN.US](https://longbridge.com/en/quote/WEN.US.md) - [HD.US](https://longbridge.com/en/quote/HD.US.md) - [BAC-Q.US](https://longbridge.com/en/quote/BAC-Q.US.md) - [BML-L.US](https://longbridge.com/en/quote/BML-L.US.md) - [BAC-L.US](https://longbridge.com/en/quote/BAC-L.US.md) - [BAC-K.US](https://longbridge.com/en/quote/BAC-K.US.md) - [BML-H.US](https://longbridge.com/en/quote/BML-H.US.md) - [BAC-N.US](https://longbridge.com/en/quote/BAC-N.US.md) - [BAC-E.US](https://longbridge.com/en/quote/BAC-E.US.md) - [MER-K.US](https://longbridge.com/en/quote/MER-K.US.md) - [BAC-O.US](https://longbridge.com/en/quote/BAC-O.US.md) - [BML-G.US](https://longbridge.com/en/quote/BML-G.US.md) - [BAC-M.US](https://longbridge.com/en/quote/BAC-M.US.md) - [BAC-B.US](https://longbridge.com/en/quote/BAC-B.US.md) - [BML-J.US](https://longbridge.com/en/quote/BML-J.US.md) - [BAC-S.US](https://longbridge.com/en/quote/BAC-S.US.md) - [BAC-P.US](https://longbridge.com/en/quote/BAC-P.US.md) - [8648.JP](https://longbridge.com/en/quote/8648.JP.md) ## Related News & Research - [Invivyd files Form 3 for director Ian Sheffield`](https://longbridge.com/en/news/297828615.md) - [Invivyd Names Chairman Marc Elia CEO, Adds New Directors](https://longbridge.com/en/news/297655443.md) - [Is Goldman Sachs Stock Outperforming the Nasdaq?](https://longbridge.com/en/news/297672766.md) - [Invivyd appoints Marc Elia as CEO; Ian Sheffield joins board](https://longbridge.com/en/news/297642699.md) - [Insider Selling: SEA (NYSE:SE) Insider Sells $171,105.00 in Stock](https://longbridge.com/en/news/297774863.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**